about RenalytixAI

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.  RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.

RenalytixAI is commercializing KidneyIntelXTM, an artificial intelligence in vitro diagnostic product intended to support physician decision making by improving identification, prediction, and risk stratification of patients with progressive kidney disease.

RenalytixAI considers there to be a significant opportunity to deliver quality-assured, regulated, AI-driven product for the chronic kidney disease (CKD) market.

A costly disease

The International Society of Nephrology estimates that over 850 million people worldwide have some form of kidney disease, approximately twice that of diabetes (422 million) and 20 times more than cancer.  By this estimate, kidney disease affects 10.4% of men and 11.8% of women worldwide.

In the US, CKD affects over 40 million adults and kills more people than breast or prostate cancer. Commonly referred to as a “silent disease” kidney disease is often asymptomatic until a majority of kidney function has been lost.  As a result, CKD is associated with significant morbidity, mortality and healthcare costs.

It is estimated that a third of adults in the US are at risk of kidney disease. This risk is greatest for those suffering from diabetes, high blood pressure, heart disease and obesity. Studies have also shown that ethnicity is a determining factor, with African Americans and Hispanic populations deemed most at risk.

latest News

30Jun

Partnership with the University of Michigan to extend KidneyIntelX™ use to broad CKD populations & Data sharing agreement with a top ten global pharmaceutical company

Renalytix AI plc announces a partnership with the University of Michigan (“UM”) to extend the application of the KidneyIntelX™ platform .. Read More →
26Jun

COVID-19 UPDATE

In the face of immense uncertainty, Renalytix AI remains committed to utilizing our scientific resources and technology to improve patient outcomes, both in chronic kidney.. Read More →
25Jun

Public filing of registration statement with SEC for a proposed Nasdaq dual-listing and global offering

Renalytix AI plc announces the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission.. Read More →